In the clinical treatment of Parkinson's disease (PD), the emergence of L-DOPA-induced dyskinesia (LID) and other motor symptoms remains a restrictive factor for the use of levodopa (L-DOPA). Our objective was to test the effect of continuous dopaminergic stimulation (CDS) on LID and the mechanism of its effect on the calcium (Ca) signaling pathway. 6-OHDA (6-hydroxydopamine)-treated rats were administered 1% CMC-Na, L-DOPA, rotigotine behenate (RGTB), and L-DOPA + RGTB, respectively, for 28 days.
View Article and Find Full Text PDF